SoftOx Solutions AS — Capital/Financing Update 2024

Jan 16, 2024

SoftOx Solutions AS; Ongoing financial restructuring - closed a conditional agreement with the lender in the NOK 40 million convertible loan

SoftOx Solutions AS; Ongoing financial restructuring - closed a conditional agreement with the lender in the NOK 40 million convertible loan

OSLO – 16th of January 2024:

Reference is made to SoftOx (the Company) press release of 11th and 16th January 2024 where the Company announced on-going work to restructure the financial situation.

The Company hereby announces that we have closed a conditional agreement with the lender in the NOK 40 million convertible loan with the due date of 15th of January 2024 to convert the debt plus accrued interests to equity in the Company within 1st of April, 2024. The terms for the agreement require that the Company successfully raise at least 25 MNOK in new share capital and the lenders in the 15 million loan plus accrued interests from spring 2023 with due date of 31. January 2024 agrees to similar conversion.

Total convertible debt including accrued interests and debt to employees of the Borrower amounts to about NOK 77 million, which will all be convertible at the same price as the price in the equity issue.

SoftOx Solutions AS

Mail: ir@soft-ox.com

Phone: (+47) 977 50 071 (Chairman of the Board Geir Almås)

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Medtech and

clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of reducing

the spread of infection and emergence of antimicrobial resistance.

For more information on SoftOx, visit www.soft-ox.com